Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China flag China · Delayed Price · Currency is CNY
37.07
-1.59 (-4.11%)
Nov 6, 2026, 11:30 AM CST

Hangzhou Biotest Biotech Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
10.3249.25169.52106.61773.63833.59
Depreciation & Amortization
23.7223.9822.6229.1723.2510.53
Other Amortization
0.780.520.110.10.080.1
Loss (Gain) From Sale of Assets
-0.25-0.250.33-0-0
Asset Writedown & Restructuring Costs
0.040.04-6.3518.78-
Loss (Gain) From Sale of Investments
-4.29-4.29-7.05-3.38-14.85-1.07
Provision & Write-off of Bad Debts
-0.12-0.123.523.67-5.593.21
Other Operating Activities
39.5916.2711.0536.27-48.3729.38
Change in Accounts Receivable
3.793.79-39.78-13.57107.84-51.4
Change in Inventory
-2.04-2.043.13-14.14-48.93-60.84
Change in Accounts Payable
8.848.84-43.09-20.43-98.94145.05
Change in Other Net Operating Assets
8.788.786.532.465.311.05
Operating Cash Flow
90.86106.47128.83131.38703.21908.12
Operating Cash Flow Growth
-3.22%-17.36%-1.94%-81.32%-22.56%103.58%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-138.95-129.87-245.05-56.42-178.92-200.2
Sale of Property, Plant & Equipment
0.642.740.080.18--
Investment in Securities
-101.86251.83-601.82126.76260.84-400
Other Investing Activities
5.1578.543.8414.790.23
Investing Cash Flow
-235.02131.7-838.2574.3696.71-599.97

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---0.24-5.56
Total Debt Issued
100--0.24-5.56
Short-Term Debt Repaid
---0.15--5.29-11
Long-Term Debt Repaid
---2.45-4.17-2.8-2.46
Lease Payments
---2.45-4.17-2.8-2.46
Total Debt Repaid
-0.23--2.6-4.17-8.08-13.46
Net Debt Issued (Repaid)
99.77--2.6-3.93-8.08-7.9
Issuance of Common Stock
3.153.1524.874.17-856.14
Repurchase of Common Stock
---43.18-14.76--
Common Dividends Paid
-105.13-159.88-83.65-234.67-320.01-20.91
Other Financing Activities
-120.15-1.33---4.56-14.09
Financing Cash Flow
-122.36-158.06-104.55-249.19-332.65813.24

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-46.18-12.6810.510.89104.91-14.82
Net Cash Flow
-312.767.44-803.48-32.55572.181,107

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-48.09-23.4-116.2374.96524.29707.92
Free Cash Flow Growth
----85.70%-25.94%82.27%
Free Cash Flow Margin
-10.64%-5.22%-20.78%16.95%27.58%38.94%
Free Cash Flow Per Share
-0.34-0.16-0.790.503.515.84
Levered Free Cash Flow
-71.54-101.94-127.36-18279.64443.47
Unlevered Free Cash Flow
-71.54-101.94-127.34-17.91279.77443.89
Free Cash Flow After Leases
-48.09-23.4-118.6870.79521.5705.46

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
--30.31-0.273.48143.6367.92
Change in Working Capital
21.0621.06-71.28-47.41-43.7132.37